RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-13.46%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$627M
AUM Growth
+$627M
(-11%)
Cap. Flow
+$19.4M
Cap. Flow
% of AUM
3.08%
Top 10 Holdings %
Top 10 Hldgs %
25.67%
Holding
102
New
6
Increased
38
Reduced
34
Closed
9
Top Buys
| 1 |
Humana
HUM
|
$14.3M |
| 2 |
Cigna
CI
|
$14.3M |
| 3 |
Pfizer
PFE
|
$13.2M |
| 4 |
McKesson
MCK
|
$9.62M |
| 5 |
AET
Aetna Inc
AET
|
$9.52M |
Top Sells
| 1 |
Biogen
BIIB
|
$20.3M |
| 2 |
Johnson & Johnson
JNJ
|
$18.6M |
| 3 |
UnitedHealth
UNH
|
$9.74M |
| 4 |
CVS Health
CVS
|
$8.39M |
| 5 |
Merck
MRK
|
$7.9M |
Sector Composition
| 1 | Healthcare | 91.99% |
| 2 | Financials | 2.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Community Health Systems
CYH
$392M
| $9.41M | 1.5% |
266,200
+133,100
| +100% | +$4.7M |
|
|
27
CVS Health
CVS
$93B
| $9.36M | 1.49% |
97,000
-87,000
| -47% | -$8.39M |
|
28
BioMarin Pharmaceuticals
BMRN
$11.3B
| $9.06M | 1.44% |
86,000
-6,000
| -7% | -$632K |
|
|
HNT
29
DELISTED
HEALTH NET INC
HNT
| $9.03M | 1.44% |
+150,000
| New | +$9.03M |
|
30
Edwards Lifesciences
EW
$47.7B
| $8.82M | 1.41% |
372,000
+204,000
| +121% | +$4.83M |
|
31
Labcorp
LH
$22.8B
| $8.79M | 1.4% |
94,284
+12,804
| +16% | +$1.19M |
|
|
CEMP
32
DELISTED
Cempra, Inc.
CEMP
| $8.3M | 1.32% |
298,000
+20,839
| +8% | +$580K |
|
|
ESRX
33
DELISTED
Express Scripts Holding Company
ESRX
| $7.77M | 1.24% |
96,000
+17,000
| +22% | +$1.38M |
|
34
Regeneron Pharmaceuticals
REGN
$59.8B
| $7.68M | 1.22% |
16,500
-2,500
| -13% | -$1.16M |
|
35
Nektar Therapeutics
NKTR
$543M
| $7.54M | 1.2% |
45,867
-16,600
| -27% | -$2.73M |
|
36
DexCom
DXCM
$30.9B
| $7.21M | 1.15% |
336,000
-32,000
| -9% | -$687K |
|
|
ABMD
37
DELISTED
Abiomed Inc
ABMD
| $7.05M | 1.12% |
76,000
-28,000
| -27% | -$2.6M |
|
|
CERN
38
DELISTED
Cerner Corp
CERN
| $6.96M | 1.11% |
116,000
+33,000
| +40% | +$1.98M |
|
|
ITCI
39
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.61M | 1.05% |
165,000
-41,000
| -20% | -$1.64M |
|
40
Zimmer Biomet
ZBH
$20.8B
| $6.58M | 1.05% |
+72,100
| New | +$6.58M |
|
41
Acadia Pharmaceuticals
ACAD
$4.34B
| $6.48M | 1.03% |
196,000
+5,000
| +3% | +$165K |
|
42
Jazz Pharmaceuticals
JAZZ
$7.99B
| $6.2M | 0.99% |
46,700
-23,300
| -33% | -$3.09M |
|
43
Alnylam Pharmaceuticals
ALNY
$58.6B
| $6.11M | 0.97% |
76,000
+14,600
| +24% | +$1.17M |
|
44
Universal Health Services
UHS
$11.6B
| $6.1M | 0.97% |
48,900
-16,100
| -25% | -$2.01M |
|
45
Cencora
COR
$57.2B
| $5.98M | 0.95% |
63,000
+21,000
| +50% | +$1.99M |
|
|
KERX
46
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $5.5M | 0.88% |
1,563,000
+1,029,000
| +193% | +$3.62M |
|
|
ICPT
47
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $5.31M | 0.85% |
32,000
+8,000
| +33% | +$1.33M |
|
|
ENDP
48
DELISTED
Endo International plc
ENDP
| $5.06M | 0.81% |
73,000
+14,024
| +24% | +$971K |
|
|
ZLTQ
49
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $5.03M | 0.8% |
157,000
+28,000
| +22% | +$897K |
|
50
Supernus Pharmaceuticals
SUPN
$2.52B
| $4.96M | 0.79% |
353,328
-63,672
| -15% | -$893K |
|